The incretin mimetic exenatide improves glycaemic control with associated weight reduction in patients with type 2 diabetes (T2DM) treated with metformin (MET) and/or a sulphonylurea (SU), or MET and/or a thiazolidinedione. As a drug's pharmacokinetics and pharmacodynamics can vary with age, we explored exenatide's efficacy and safety for patients <65 y and Ն65 y in this post-hoc analysis. METHODS: Patients completing Ն3 y of exenatide treatment on background therapies of MET and/or an SU (N = 217, age 58 Ϯ 10 y, 64% male, weight 99 Ϯ 18 kg, HbA1c 8.2 Ϯ 1.0%, fasting plasma glucose [FPG] 9.6 Ϯ 2.5 mmol/L, diabetes duration 8 Ϯ 6 y; mean Ϯ SD) had statistically significant (P < 0.05) mean (ϮSE) changes in HbA1c (-1.0 Ϯ 0.1%), FPG (-1.3 Ϯ 0.2 mmol/L), and weight (-5.3 Ϯ 0.4 kg). The two subgroups (baseline age <65 y, N = 161, 53 Ϯ 7 y, and Ն65 y, N = 56, 70 Ϯ 4 y) differed in baseline duration of diabetes (7 Ϯ 6 y, 11 Ϯ 6 y). RESULTS: The mean (ϮSE) changes in HbA1c (-0.9 Ϯ 0.1%, -1.2 Ϯ 0.2%), weight (-5.2 Ϯ 0.5 kg, -5.4 Ϯ 0.6 kg), and FPG (-1.1 Ϯ 0.3 mmol/L, -1.8 Ϯ 0.3 mmol/L) were not statistically different for the two subgroups (all, P > 0.1). In patients completing 3.5 y of exenatide, changes in lipids for the <65 y subgroup (N = 118) and Ն65 y subgroup (N = 33) were not statistically different, as follows (mmol/L): HDL cholesterol (+0.21 Ϯ 0.02, +0.25 Ϯ 0.03), LDL cholesterol (-0.28 Ϯ 0.09, -0.37 Ϯ 0.15), total cholesterol (-0.26 Ϯ 0.09, -0.33 Ϯ 0.16), and triglycerides (-0.49 Ϯ 0.17, -0.52 Ϯ 0.14) (all, P > 0.2). Nausea and hypoglycaemia, the most common adverse events, occurred at similar rates in both subgroups. The only case of severe hypoglycaemia occurred in a patient <65 y whose background therapies were MET and an SU. CONCLUSION: In summary, in this open-label extension study of T2DM patients treated with MET and/or an SU, exenatide exposure Ն3 y resulted in similar safety profiles and improvements in glycaemic control and lipid concentrations, with associated weight reductions for patients Ն65 y and <65 y.
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PDB6 DATABASE ASSESSMENT OF THE EFFECTIVENESS OF BRAND VERSUS GENERIC ROSIGLITAZONE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Katzir I, Loebstein R,Vasterman landes J, Halkin H, Lomnicky Y Maccabi Healthcare Services, Tel Aviv, Israel OBJECTIVES: To compare the effectiveness of brand rosiglitazone maleate (BRM) versus generic rosiglitazone HCl (GRH) in patients with type 2 diabetes mellitus, using computerized records of a health care organization. METHODS: Comparison of HbA1C reduction in patients starting treatment with either BRM (n = 740) or GRH (n = 306) in the years [2004] [2005] . RESULTS: BRM users were older (63.5 Ϯ 11 vs. 61.7 Ϯ 10 years p < 0.001) and presented more cardiovascular disorders (38% vs. 25%, p < 0.001) with no differences in gender distribution, rates of hypertension or use of concomitant oral hypoglycemic drugs. Use of concomitant insulin was more frequent (17.7% vs. 6.2%, p < 0.0001), rates of dispensed rosiglitazone doses >4 mg/d (65.3% vs. 48.5%, p < 0.001) and treatment duration was longer (9.3 Ϯ 6.2 vs. 5.2 Ϯ 2.2 months, p < 0.001) with the generic formulation. Baseline HbA1C levels were higher (9.0 Ϯ 1.5 vs. 8.6 Ϯ 1.2%, p < 0.001) and the absolute decrease in HbA1C levels was greater in the GRH group (-1.2% Ϯ 1.6% vs. -0.5% Ϯ 1.7%, p < 0.001). On multiple regression analysis, the decrease in HbA1C (dependent variable) was associated mainly with initial HbA1C level (partial r2 = 0.30). Rosiglitazone formulation (partial r2 = 0.02), age, treatment duration and concomitant insulin (partial r2 = 0.006) were all significant but minor predictors, with no effect of rosiglitazone daily dose. Mean regression-predicted decreases in HbA1C (with 95% CL) were not significantly different between the two rosiglitazone formulations: -1.6% (-4.3% to +1.1%) for GRH and -1.1% (-3.8% to +1.6%) for BRM. CONCLUSION: In this retrospective database analysis, we found no evidence of different effectiveness of generic vs. brand rosiglitazone in lowering HbA1C levels. The objective of this study was to compare the rate of micro-and macrovascular complications in type 2 diabetes mellitus (T2DM) patients, from increased insulin use due to the addition of inhaled human insulin Exubera (EXU) as a treatment option versus subcutaneous (sc) insulin alone using the Economic Assessment of Glycemic Control and Long-term Effects(Eagle) model. METHODS: The model included uncontrolled T2DM patients eligible for insulin. Long-term consequences were based on risk equations derived from DCCT, UKPDS and WESDR. The model used Freemantle's estimates for year one. In the arm where EXU and sc insulin were available, 43% of patients initiated insulin therapy (35% inhaled and 8% sc insulin) versus 16% when only sc insulin was available. The subsequent yearly increase in insulin uptake was based on data from the DIN-LINK study. The model assumed 8% of patients remained on sc insulin. RESULTS: The mortality rate observed after 10 years was 34.5% versus 36.3% with inhaled and sc insulin versus sc insulin respectively. Complications observed after 10 years, when inhaled and sc insulin were available vs. sc insulin alone, were 14.7% vs. 16.1% for myocardial infarction and stroke, 5.2% vs. 5.9% for proliferative retinopathy, 43.4% vs. 47.3% for microalbuminuria and 14.1% vs. 17.2% for clinical neuropathy. In sensitivity analyses, EXU's advantages remained when insulin uptake was capped at 60% (i.e. always at least 40% on OADs). CONCLUSION: Delaying insulin initiation increases the rate of complications. The results showed that when insulin use is increased due to the availability of inhaled insulin, a reduction in all-cause mortality and the number of complications should be observed. Exubera has the potential to improve diabetes management by overcoming barriers to insulin initiation in T2DM patients, and could help prevent more longterm complications associated with T2DM.
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